@article{8c276452ee9a4718a28c42887d7c8c81,
title = "Comparison of live attenuated cold-adapted and avian-human influenza A/Bethesda/85 (H3N2) reassortant virus vaccines in infants and children",
abstract = "Randomized, placebo-controlled studies with 103–107 50% tissue-culture infectious dose (TCID50) of avian-human (ah) and cold-adapted (ca) influenza A/Bethesda/85 (H3N2) reassortant viruses were completed in 106 seronegative young children 6–48 months of age. Although the reassortants differed in six of eight RNA segments, they exhibited similar properties in level of attenuation, infectivity, immunogenicity, and efficacy. The 50% human infectious dose was 104.6 TCID50 for ah and 104.4 for ca vaccines. Both reassortants were satisfactorily attenuated with restricted replication and were no more reactogenic than placebo. The mean peak titer of virus shed was 101.5 (ah) to 102.0 (ca) TCID50/ml, and each of 37 isolates tested retained their characteristic vaccine phenotypes. Infection with ah or ca virus conferred immunity to experimental challenge with homologous virus. These findings indicate that both ah and ca influenza A/Bethesda/85 (H3N2) reassortants should be suitable vaccine candidates for use in healthy infants and young children.",
author = "Steinhoff, {Mark C.} and Hasley, {Neal A.} and Wilson, {Modena H.} and Burns, {Barbara A.} and Samorodin, {Roberta K.} and Fries, {Louis F.} and Murphy, {Brian R.} and Clements, {Mary Lou}",
note = "Funding Information: Received 16 October 1989; revised 16 February 1990. Presented in part at the Society for Pediatric Research, April 1987, Anaheim, CA, and at the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 1988, Los Angeles. Written informed consent was obtained from the parents of participating children after receiving a detailed explanation of the purpose of the study, the procedures, and the potential risks and benefits to the child. Guidelines for human experimentation of the US Department of Human Services, the Joint Committee for Clinical Investigation of the Johns Hopkins University School of Medicine, and the Clinical Research Subpanel ofthe National Institute of Allergy and Infectious Diseases were followed. Supported by the National Institutes of Health (AI-62515). Reprints and correspondence: Dr. Mark C. Steinhoff, Johns Hopkins University Center for Immunization Research, 624 N. Broadway, Baltimore, MD 21205.",
year = "1990",
month = aug,
doi = "10.1093/infdis/162.2.394",
language = "English (US)",
volume = "162",
pages = "394--401",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "2",
}